Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice

Haemophilia

Volumn 17, Issue 2, 2011, Pages 288-295

  Qadura, M ^a   Waters, B ^a   Burnett, E ^a   Chegeni, R ^a   Hough, C ^a   Othman, M ^a   Lillicrap, D ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Balb c; C57BL 6; FVIII antibodies; FVIII inhibitors; FVIII T and B cell immune response; Haemophilia; Th1 Th2 micro environment

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; FLOW CYTOMETRY; GENETIC STRAIN; HEMOPHILIA A; MALE; MOUSE; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; SECONDARY IMMUNE RESPONSE; T LYMPHOCYTE; TH1 CELL;

ANIMALS; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; IMMUNOGLOBULINS; MICE; MICE, INBRED BALB C;

EID: 79951794286     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02397.x     Document Type: Article

References (28)

1. Batlle J, Gomez E, Rendal E et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 321-6.
2. Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang 1999; 77(Suppl. 1): 17-20.
3. Lacroix-Desmazes S, Wootla B, Dasgupta S et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol 2006; 177: 1355-63.
4. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-75.
5. Stavnezer J, Amemiya CT. Evolution of isotype switching. Semin Immunol 2004; 16: 257-75.
6. Saenko EL, Ananyeva NM, Kouiavskaia DV et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 8: 1-11.
7. Hu G, Guo D, Key NS, Conti-Fine BM. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007; 97: 788-94.
8. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-73.
9. Kuroda E, Kito T, Yamashita U. Reduced expression of STAT4 and IFN-gamma in macrophages from BALB/c mice. J Immunol 2002; 168: 5477-82.
10. Peng Y, Falck-Pedersen E, Elkon KB. Variation in adenovirus transgene expression between BALB/c and C57BL/6 mice is associated with differences in interleukin-12 and gamma interferon production and NK cell activation. J Virol 2001; 75: 4540-50.
11. Guler ML, Jacobson NG, Gubler U, Murphy KM. T cell genetic background determines maintenance of IL-12 signaling: effects on BALB/c and B10.D2 T helper cell type 1 phenotype development. J Immunol 1997; 159: 1767-74.
12. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
13. Connelly S, Andrews JL, Gallo AM et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
14. Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
15. Freedman J, Garvey MB. Immunoadsorption of factor VIII inhibitors. Curr Opin Hematol 2004; 11: 327-33.
16. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
17. Dasgupta S, Navarrete AM, Delignat S et al. Immune response against therapeutic factor VIII in hemophilia A patients - a survey of probable risk factors. Immunol Lett 2007; 110: 23-8.
18. Bauer H, Ahmad B, Schwarz R. Comparable long-term persistence of anti-FVIII antibodies in hemophilic E17 mice on different genetic backgrounds despite significant differences in the amplitude of the immune responses. Blood (ASH Annual Meeting Abstracts) 2006; 108. Abstract 1027.
19. Fox JG, Beck P, Dangler CA et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 2000; 6: 536-42.
20. Kohm AP, Sanders VM. Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo. J Immunol 1999; 162: 5299-308.
21. Koo GC, Gan YH. The innate interferon gamma response of BALB/c and C57BL/6 mice to in vitro Burkholderia pseudomallei infection. BMC Immunol 2006; 7: 19.
22. Scott MJ, Hoth JJ, Gardner SA, Peyton JC, Cheadle WG. Genetic background influences natural killer cell activation during bacterial peritonitis in mice, and is interleukin 12 and interleukin 18 independent. Cytokine 2004; 28: 124-36.
23. Liu T, Matsuguchi T, Tsuboi N, Yajima T, Yoshikai Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect Immun 2002; 70: 6638-45.
24. Wells CA, Ravasi T, Faulkner GJ et al. Genetic control of the innate immune response. BMC Immunol 2003; 4: 5.
25. Sasgary M, Ahmad RU, Schwarz HP, Turecek PL, Reipert BM. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
26. Greene JA, DeVecchio JL, Gould MP, Auletta JJ, Heinzel FP. In vivo and in vitro regulation of type I IFN synthesis by synergistic effects of CD40 and type II IFN. J Immunol 2006; 176: 5995-6003.
27. White GC II, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost 2005; 3: 1676-81.
28. Hay CR, Ollier W, Pepper L et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.